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Background: Omega-3 poly-unsaturated fatty acids (ω-3 PUFAs) have demonstrated to be beneficial in the
prevention of cardiovascular disease, however, the mechanisms by which they perform their cardiovascular
protection have not been clarified. Intriguingly, some of these protective effects have also been linked to HDL. The
hypothesis of this study was that ω-3 PUFAs could modify the protein cargo of HDL particle in a triglyceride non-
dependent mode. The objective of the study was to compare the proteome of HDL before and after ω-3 PUFAs
supplemented diet.
Methods: A comparative proteomic analysis in 6 smoker subjects HDL before and after a 5 weeks ω-3 PUFAs
enriched diet has been performed.
Results: Among the altered proteins, clusterin, paraoxonase, and apoAI were found to increase, while fibronectin,
α-1-antitrypsin, complement C1r subcomponent and complement factor H decreased after diet supplementation
with ω-3 PUFAs. Immunodetection assays confirmed these results. The up-regulated proteins are related to anti-
oxidant, anti-inflammatory and anti-atherosclerotic properties of HDL, while the down-regulated proteins are related
to regulation of complement activation and acute phase response.
Conclusions: Despite the low number of subjects included in the study, our findings demonstrate that ω-3 PUFAs
supplementation modifies lipoprotein containing apoAI (LpAI) proteome and suggest that these protein changes
improve the functionality of the particle.
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In the last decades, different observational and interven-
tion studies have demonstrated a beneficial effect of
diets enriched in omega-3 poly-unsaturated fatty acids
(ω-3 PUFAs) in the prevention of cardiovascular disease
(CVD). Most common ω-3 PUFAs are α-linolenic acid
C18:3 n-3, present in plants, and eicosapentaenoic acid
(EPA) and docosahexaenoic acid (DHA), found in fish
oil. The dose–response (3–4 g/day) hypotriglyceridemic
effect (fasting and postprandial) is the best defined meta-
bolic effect of ω-3 PUFAs [1]. The mechanism for this* Correspondence: elena.burillo@fjd.es
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reproduction in any medium, provided the orlipid lowering effect seems to be due to activation of
peroxisome proliferator-activated receptors (PPAR) [2].
Other potential beneficial effects of ω-3 PUFAs include
reduction of susceptibility to ventricular arrhythmia [3];
antithrombogenic and antioxidant effect [4]; retardation
of the atherosclerotic plaque growth by reduced expres-
sion of adhesion molecules and platelet-derived growth
factor [4] and anti-inflammatory effect [5]; promotion of
endothelial relaxation by induction of nitric-oxide pro-
duction, and mild hypotensive effect [6]. All these effect
are explained because diet EPA and DHA are rapidly
incorporated into the cellular membrane phospholipids
where carry out their potential attributed actions [7].
Interestingly, several of the beneficial effects attribut-
able to ω-3 PUFAs have also been linked to HDL. HDL
has been involved in anti-thrombosis and endothelial
dysfunction [8], anti-inflammatory effect [9], inhibitiontd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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plement system, inhibition of proteolysis and regulation
of acute phase response [12]. Omega-3 PUFAs do not
substantially modify the cholesterol transported by the
HDL but, it is now assumed that HDL cholesterol is not
a good marker of the functional capacities of the par-
ticle. Recent studies have confirmed that protein content
of HDL is complex, and it is more related with certain
anti-atherogenic properties of HDL than HDL choles-
terol [13].
The hypothesis of this study was that ω-3 PUFAs
could modify the protein cargo of HDL particle in a tri-
glyceride non-dependent mode. Regarding this, the ef-
fect of ω-3 PUFAs would be directly related, at least in
part, to cardioprotective actions of HDL particle. In
order to elucidate this hypothesis, a comparative prote-
omic analysis of HDL particle before and after a ω-3
PUFAs enriched diet has been performed in a smoking
healthy male volunteers group, a population charac-
terised by dysfunctional HDL particles [14] in which




Clinical, biochemical and dietary characteristics
The study group was composed of 6 male smokers, all of
whom completed the experiment. Tobacco consumption
was used as a model to study dysfunctional HDL particle.
Their mean age was 43.0 (28.5-51.0) (median (interquar-
tile range)) and their mean tobacco consumption was 25.5
(20.0-31.3) cigarettes per day. Table 1 shows the mainTable 1 Clinical characteristics of study subjects at base line a
Basal situation
Body mass index, Kg/m2 26.1 (24.0-28.0)
Waist circunference, cm 95.0 (87.1-98.5)
Systolic blood pressure, mmHg 134 (115–139)
Dyastolic blood pressure, mmHg 78.0 (67.7-85.5)
Total cholesterol, mg/dL 208 (186–232)
LDL cholesterol, mg/dL 136 (104–170)
HDL cholesterol, mg/dL 49.0 (41.0-61.5)
Non-HDL cholesterol, mg/dL 155 (122–191)
Triglycerides, mg/dL 92.5 (74.2-127)
Apo A-I, mg/dL 143 (136–166)
Apo B, mg/dL 111 (90.6-145)
Lp(a), mg/dL 57.3 (16.3-59.1)
CRP, mg/L 2.55 (1.47-4.45)
Creatinine, mg/dL 0.86 (0.82-0.99)
Glucose, mg/dL 87.5 (79.0-93.5)
Variables are expressed as median (interquartile range). Apo denotes apolipoproteinclinical variables at baseline and at the end of the inter-
vention. As expected, due to the low dose of ω-3 PUFAs
supplementation, there were not changes in the lipids
parameters. Baseline diet assessment showed a mean en-
ergy intake of 2847 (2671–2991) kcal with a high con-
sumption of total fat 37.6 (35.8-40.4)%, a low intake of
carbohydrates 42.8 (39.0-47.6)%, and a protein intake of
14.8 (14.3-15.8)%. Marine and non-marine omega-3 fatty
acids intake was 0.60 (0.25-1.07) g/day and 1.36 (1.19-
1.98) g/day, respectively. Physical activity questionnaire
results showed a mean of 64.2 (36.5-81.3) METs/week.
Dietary parameters and exercise level were stable through-
out the study as FFQ and physical activity questionnaire
performed at the end of the study revealed (data not
shown).
Omega-3 PUFAs compliance
Omega-3 PUFAs supplements were well tolerated by all
subjects who did not show any side effect. According to
participant’s reports and recounts of empty packages,
compliance with the supplements was 100%.
Proteomic results
Proteomic analysis revealed that 28 spots were differen-
tially expressed (p < 0,05) between both study periods. By
mass spectrometry, 16 out of the 28 spots were identi-
fied: 10 spots were identified up-regulated after ω-3
PUFAs treatment and 6 spots were down-regulated. The
up-regulated spots corresponded to apoAI, clusterin,
paraoxonase (PON1), fibrinogen β, haptoglobin-related
protein (HPTR) and immunoglobulin kappa chain
C region; and the down-regulated spots corresponded tond after 5 weeks of ω-3 PUFAs supplementation
















. CRP denotes C Reactive Protein.
Table 2 Identification results of proteins differentially expressed in basal and after ω-3 PUFAs supplementation























837 Apolipoprotein A-I 0.044 1.18 Up-regulated P02647 APOA1 87 42 10 1 30.8 5.56
997 Clusterin 0.029 1.3 Up-regulated P10909 CLUS 735 47 30 8 53 5.89
610 Fibrinogen β 0.048 1.1 Up-regulated P02675 FIBB 233 49 29 4 56.6 8.54
612 Fibrinogen β 0.045 1.1 Up-regulated P02675 FIBB 140 45 20 1 56.6 8.54
721* Clusterin 0.02 1.4 Up-regulated P10909 CLUS 519 23 11 53 5.89
Apolipoprotein A-I 0.02 1.4 Up-regulated P02647 APOA1 478 39 13 30.8 5.56
Haptoglobin-related protein 0.02 1.4 Up-regulated P00739 HPTR 477 26 12 39.5 6.63
732 Haptoglobin-related protein 0.015 1.37 Up-regulated P00739 HPTR 79 31 14 4 39.5 6.63
965 Serum paraoxonase 0.003 1.6 Up-regulated P27169 PON1 142 15 9 4 39.8 5.08
970 Serum paraoxonase 0.003 1.97 Up-regulated P27169 PON1 411 56 24 8 39.8 5.08
973 Serum paraoxonase 0.003 1.86 Up-regulated P27169 PON1 235 31 14 4 39.8 5.08
825* Ig kappa chain C region 0.036 1.27 Up-regulated P01834 IGKC 872 86 8 11.6 5.87
Apolipoprotein A-I 0.036 1.27 Up-regulated P02647 APOA1 397 52 15 30.8 5.56
578* α-1-antitrypsin 0.001 0.74 Donw-regulated P01009 A1AT 364 51 18 46.7 5.59
986* Complement C1r subcomponent 0.018 0.85 Donw-regulated P00736 C1R 1601 65 45 80.1 6.21
987* Serum Albumin 0.032 0.85 Donw-regulated P02768 ALBU 1114 75 46 69.3 6.3
Ig mu Chain C region 0.032 0.85 Donw-regulated P01871 IGHM 987 57 25 49.3 6.8
Complement C1r subcomponent 0.032 0.85 Donw-regulated P00736 C1R 784 46 28 80.1 6.2
324 Complement Factor H 0.017 0.72 Donw-regulated P08603 CFAH 72 16 19 1 14.4 6.21
980* Fibronectin 0.01 0.66 Donw-regulated P02751 FN1 1434 26 40 262.5 5.71
981* Fibronectin 0.002 0.67 Donw-regulated P02751 FN1 1437 30 48 262.5 5.71
Spots label with a * denotes identification by Orbitrap. Positive fold changes denote proteins up-regulated while negative fold changes denote decrease protein expression after the supplementation. MW denotes
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munoglobulin mu chain C region, complement C1r
subcomponent and complement factor H. Mass spec-
trometry identification results are presented in Table 2
and a representative 2D image is shown in Figure 1.
Moreover, in Figure 2 a representative section of the gel
labelled with the DIGE dyes is presented. In Additional
file 1: Table S1 the normalized volume of each spot in
every gel is detailed. To better understand the differ-
ences existing between basal and after-treatment HDL
proteome, proteins identified were classified by bio-
logical function (Table 3).Confirmation of proteomic results by immunodetection
methods
Clusterin increase observed by proteomics was confirmed
by immunodetection (p < 0.05). The fold change observed
in clusterin measured by ELISA was 2.18 (basal situation:
3.81E-7 (3.72E-7-3.90E-7); after the supplementation:
8.29E-7 (5.06E-7-1.17E-6). Comparison of HDL PON1Figure 1 Differentially expressed protein spots identified by DIGE ana
IPG strips for the first dimension and 10% polyacrylamide for the second dim
nm excitation/emission wavelengths. Spots detected by the analysis software
up-regulated (red) after the ω-3 PUFAs supplementation and six were significbetween the study situations showed an increased in en-
zyme activity (fold change: 1.22) after ω-3 PUFAs supple-
mentation, but it did not achieve statistical significance
(basal situation: 4.47 (3.10-5.30); after the supplementa-
tion: 6.68 (4.24-11.5)).
Moreover, Milliplex MAP assays were performed to
measure apoAI, apoE and apoCIII, proteins known to be
constituents of HDL and to be related to cardiovascular
disease. Significant results are shown in Figure 3.Discussion
A recent meta-analysis of 29 clinical trials including
more than 35,000 high risk cardiovascular patients has
explored the effects of ω-3 PUFAs and it has shown a re-
duction in total mortality associated with the use of
these fatty acids [16]. Similar results were obtained from
the meta-analysis of 12 studies including 32,779 patients
from randomised controlled trials of fish oil as dietary
supplements [17]. Both independent studies have con-
cluded that fish oil supplementation was associated withlysis. Proteins were extracted as described and separated in pH 3–10
ension. The image was acquired on a Typhoon 9400 scanner at 633/670-
are indicated. Ten protein spot-features were found to be significantly
antly down-regulated (blue) in Lp-AI of smoker participants.
Figure 2 Representative section of the 2D-DIGE proteome map
of basal and after the ω-3 PUFAs supplementation. Proteins
were labeled with Cy3 (basal situation) and Cy5 (after the ω-3 PUFAs
supplementation). An internal standard comprised of equal amount
of proteins from all samples (basal and after the treatment) was
labeled with Cy2 and included in all gels. The green spots indicate
downregulated proteins, while the red spots indicate upregulated
proteins after the ω-3 PUFAs supplementation. Some of the most
representative identified proteins that showed significantly altered
expression after ω-3 PUFAs supplementation are indicated with
arrows and labeled with the respectives protein entry name.
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mechanisms of these pleiotropic effects of fish oil remain
mostly unknown [18]. In spite of evident similarities be-
tween the protective cardiovascular action of ω-3 PUFAs
and HDL, no previous studies had explored the effects
of ω-3 PUFAs on protein composition, other than apoAI,
on HDL.
Proteomic analysis revealed that some proteins asso-
ciated to HDL particle were significantly up- or down-
regulated in smoking healthy male subjects after 5 weeks
consuming a ω-3 PUFAs enriched diet. The down-

















Immunoglobuling mu chain C regionresponse, complement system regulation and regulation
of platelet activation, while proteins up-regulated after
the treatment were proteins implicated in lipid metabol-
ism, coagulation, signal transduction, proteolysis regula-
tion, and protection against oxidation.
In this study, we observed an increase in PON1 pro-
duced by the ω-3 PUFAs supplementation. PON1 activ-
ity was also measured and, although it did not reach
statistical significance, activity was higher after the treat-
ment. It is clearly demonstrated that the higher the level
of paraoxonase in HDL, higher is the protective effect of
the particle [19]. Taken together, this suggests that HDL
cardiovascular functions could be improved by PON1
increase. However, it must be further studied.
Interestingly, clusterin, one of the most abundant pro-
teins in HDL, was also up-regulated after ω-3 PUFAs
enriched diet. Although the role of clusterin is not yet
fully understood, it is known that administration of an
oral clusterin-peptide significantly improves HDL anti-
inflammatory properties in animal models [20]. The
clusterin increase observed in this study supports the
cardioprotective effect of ω-3 PUFAs.
Three well-known proteins related to lipid metabolism
and transport, apoAI, apoE and apoCIII, were also
increased by the ω-3 PUFAs addition. Apolipoprotein AI is
the major protein component of HDL. ApoAI protects
from atherosclerosis development by its participation in
cholesterol efflux and through its antiinflamatory and anti-
oxidant properties. ApoAI by itself is able to reduce oxi-
dized lipids and its inflammatory effects [21-23]. Many
lines of evidence indicate that apoE plays a role in modu-
lating atherogenesis promoting cholesterol efflux from
macrophages [24]. Studies made in transgenic mice have
shown that apoE-deficient animals, which develop
hypercholesterolemia and are prone to spontaneous athero-
sclerosis, show decreased lesion size when overexpressingBiological Function
Lipid transport and metabolism
Apoptosis, Complement system regulation, innate immunity
Coagulation, signal transduction
Proteolysis
Toxic metabolites hydrolysis, inhibition of LDL oxidation
Complement system regulation, innate immunity
Acute phase response, coagulation
Immune system, complement system regulation
Immune system, complement system regulation
Acute phase response, angiogenesis, cellular adhesion
Transport, regulation of colloidal osmotic pressure, platelet activation
Innate immunity
Figure 3 Expression levels of apoAI, apoCIII and clusterin. Protein expression levels were divided by total protein concentration in order to
normalize values. Expression level of apoAI and apoCIII were measured by MILLIPLEX MAP assays and clusterin levels was measured by ELISA in
participants Lp-AI particles. Changes in protein expression level were all of them statistically significant (p < 0,05).
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ate together to optimize mobilization of macrophage chol-
esterol, a process critical to limiting plaque development.
The observation of apoE increasing levels after ω-3 PUFAs
in this study is also in agreement with an improvement in
the protective properties of the particle. In this study, an
increase in apoCIII protein level has been observed after
ω-3 PUFAs supplementation. ApoCIII is present in HDL,
but it is also a major protein in VLDL and LDL. ApoCIII
has been related to elevated VLDL, LDL cholesterol, TG
levels and cardiovascular risk [25]. It was demonstrated
that the presence of ApoCIII in HDL is related to
diminished cholesterol efflux [26]. One possible explan-
ation is that, although no changes in the lipid profile
were observed, changes or redistribution of proteins be-
tween proatherogenic lipoproteins, VLDL and LDL, to
cardioprotective HDL were actually possible.
The complement system is activated by tobacco con-
sumption [27] and in vitro studies indicate that HDL blocks
the assembly of the terminal complement attack complex
on endothelial cells [28]. Supporting this observation, our
data probably indicate that HDL is involved in the regula-
tion of complement activation by tobacco. Decrease in
fibronectin and A1AT, two proteins related to acute phase
response [12] and induced by smoking [29,30], is also an-
other sign of the improvement in HDL protective capabil-
ities recovered by ω-3 PUFAs supplementation.
As far as we know, this is the first HDL proteomic study
carried out with smokers and one of the few proteomic
analysis made with ω-3 PUFAs [31-33]. This study suggests
that ω-3 PUFAs modify the particle composition in some
proteins that have been clearly associated with cardiovas-
cular protection. However, the sample size is small and
further analysis is necessary to extract final conclusions.
These results uncover a potential mechanism that could,
at least partially, explain some of the benefits of ω-3
PUFAs.
Conclusions
In conclusion, as expected, low doses of omega-3 fatty
acid supplementation do not have effect in the lipidprofile. However, they modify HDL proteome, suggesting
a positive change in the functionality of the particle in
smoking men. Functional studies and in-deep proteomic
studies will be important for the best knowledge of the
particle. If the observed changes in the protein cargo of
HDL have clinical implications must be further studied.
Methods
Subjects
The study group was composed by 6 unrelated smoking
(≥20 cigarettes/day in the last three months) healthy
male volunteers who underwent a routine medical
examination in the Hospital Universitario Miguel Servet
(Zaragoza, Spain). The study was approved by the local
ethical committee and informed consents were obtained
from all participant. Clinical examination and blood tests
were performed. Inclusion criteria were: age 16–65 years
old and normolipidemia defined as cholesterol
LDL < 190 mg/dL and triglycerides (TG) < 150 mg/dL.
Exclusion criteria were: current use of drugs that modify
lipid or glucose metabolism; anti-inflammatory drugs,
included statins, fibrates, ezetimibe, resins, aspirin, non-
steroidal drugs, corticoids, immunodepressors, and vita-
min complexes; current acute illness (including hepatic
illness, diabetes mellitus, kidney illness, cancer and thy-
roid illness non controlled); parental history of dyslipide-
mia and ω-3 PUFAs allergy; alcohol consumption
(> 30 g/day of ethanol) and any condition that, in the re-
searcher opinion, could interfere with the study.
Study design
This study was designed as a 5 weeks open study in
which 2 g/day (1 g/capsule twice a day) of ω-3 PUFAs,
in the commercial format of Omacor© (Ferrer Interna-
cional), were administrated to participants. Basal and
after the 5 weeks of supplementation, the lipid profile
and the HDL proteome were analyzed.
Plasma samples
Ten mL of blood before and after ω-3 PUFAs enriched
diet were collected on Vacutainer tubes with EDTA as
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dium azide and the protease inhibitor Pefabloc SC
(Roche) were added to plasma at a concentration of 1.5
and 0.5 mM, respectively. All samples were stored at
−80°C until they were processed.
Quantification of lipids and lipoproteins
Total serum cholesterol and triglyceride levels were
quantified enzymatically with a Beckman Synchron CX7
analyzer (Boehringer Mannheim, Ingelheim am Rhein,
Germany). HDL cholesterol was measured after precipi-
tation of apolipoprotein B-containing lipoproteins with
Mg++ phosphotungstate (Boehringer Mannheim, Ingel-
heim am Rhein, Germany). LDL cholesterol was calcu-
lated by the Friedewald formula [34].
Dietary and physical activity assessment
Before the study, participants were instructed to main-
tain their usual dietary and physical activity patterns
throughout all study to avoid changes that could alter
the HDL composition. At baseline and final visits, a
Spanish validated 137-item food frequency questionnaire
(FFQ) and The Minnesota Leisure Time Physical Activ-
ity Questionnaire were performed [35,36]. The FFQ
included the consumption frequency of each of the 137-
item food by choosing between nine possibilities (from
never or less than once per month to six or more times
per day) and the portion size. The total energy and nu-
trient intake were calculated based on previously vali-
dated Spanish food composition tables [35].
Isolation of HDL by Fast Protein Liquid Chromatography-
affinity cromatography (FPLC-AC)
FPLC-AC analysis was carried out on an ÄKTA FPLC
system (GE Healthcare, Waukesha, WI, USA) equipped
with a fraction collector. Briefly, fractions of 2 mL of
plasma from a single sample were applied to the anTi-
ApoAI affinity column made with a 5 mL HiTrapTM
NHS-activated HP (GE Healthcare) coupled to 5 mg of
antibody against human apoAI (BioDesign Inter-
national). Firstly, 10 mL of PBS were used to ensure the
equilibration of the column. The binding reaction was
performed in a saline buffer (0,1 M NaHCO3, 0,5 M
NaCl, 1 mM EDTA, pH 8,0) at a flow rate of 1 mL/min
with a maximum pressure of 0,5 MPa. When the non-
binding fraction was washed, buffer was changed to elu-
tion buffer (0,1 M glycine, 0,5 M NaCl, 10% dioxane, pH
2,8) at the same flow rate. HDL was collected using a
Frac 900 fraction collector (GE Healthcare) at 4°C as a
single 5 mL fraction over 1 mL of equilibration buffer
(0,5 M Tris–HCl, pH 8) to quickly neutralize the acid
pH and to prevent protein degradation. HDL fraction
was then concentrated to 200 μL using Amicon Ultra 10
KDa filters (Millipore, Billerica, MA, USA) at 3000 rpmfor 35–40 minutes at 4°C. Total protein concentration
was calculated by RC/DC Protein assay (BioRad). Finally,
samples were treated with the 2-D Clean-Up Kit
(GE Healthcare).
Fluorescence labelling
Three groups were defined for labelling: pooled internal
standard, before ω-3 PUFAs and after ω-3 PUFAs enriched
diet. Labelling was made following the protocol provided
in the kit. A total of 50 μg of each type of HDL sample
was labelled with one of the three CyDye DIGE Fluors
(GE Healthcare). CyDyes were reconstituted in anhydrous
dimethylformamide and combined with samples at a ratio
of 400 pmol of CyDye to 50 μg of protein. Labelling was
performed on ice and in the dark for 30 min. The reaction
was then quenched by incubating with 1 μL of 10 mM
lysine on ice and in the dark for 10 min.
2-D Gel Electrophoresis
Firstly, immobilized pH gradient (IPG) strips were equi-
librated in Destreak rehydratation solution (GE Health-
care) in which anfolites were added. The three labelled
protein samples were combined and were focused on
24 cm, 3–10 IPG strips (GE Healthcare) using an IPG-
phor focusing apparatus (GE Healthcare, Waukesha, WI,
USA). Once first dimension electrophoresis had finished,
IPG strips were equilibrated with dithiothreitol (DTT)
and iodoacetamine buffers. Then, proteins were sepa-
rated by electrophoresis on 10% polyacrylamide Tris-
glycine gels using an Ettan DALT II System (GE Health-
care, Waukesha, WI, USA).
DIGE Analysis
The gels were scanned with a Typhoon 9400 scanner (GE
Healthcare, Waukesha, WI, USA). Spot detection, quanti-
fication and image matching were performed with Progen-
esis SameSpots software (Nonlinear Dinamics, Newcastle
upon Tyne, UK). Finally, 2-D gels were fixed in 30%
methanol, 7.5% acetic acid, and stained with a silver ni-
trate protocol compatible with mass spectrometry for pro-
tein identification. Relative protein quantification of HDL
samples before and after ω-3 enriched diet was performed
using Progenesis SameSpots software (Nonlinear
Dinamics, Newcastle upon Tyne, UK). The Cy2-labelled
pooled internal standard on every gel allowed accurate
relative quantification of protein spot features across dif-
ferent gels. Student's t-test was used to identify differences
in relative abundances of protein spot-features.
In-gel digestion
Protein spots were excised manually from 2-D gels.
Briefly, spots were washed with water, ammonium bicar-
bonate (25 mM NH4HCO3), acetonitrile (ACN) and a
freshly made mix of potassium ferricyanide 30 mM and
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ples were reduced and alquilated by incubation with DTT
(10 mM) at 60°C during 45 min followed by incubation
with iodoacetamide (50 mM) at room temperature during
30 minutes. Finally, proteins were trypsin digested over-
night at 37°C (2,5 ng/μl, ratio enzyme:protein 1:20, Tryp-
sin gold, Promega). Digestion was stopped by addition of
0.5% trifluoroacetic acid (TFA) and tryptic peptides were
extracted sequentially with increasing concentrations of
ACN in H2O. Peptides were concentrated and desalted by
passing them through ZipTip C18 columns (Millipore)
following the manufacturer’s instructions and eluting with
50%ACN/0,1%TFA/H2O.Mass spectrometry analyses
Sample (0,4 μl) and matrix (0,8 μl saturated solution of
alpha-Cyano-4-hydroxycinnamic acid in 50% ACN/0.1%
TFA/H2O) were spotted in duplicate onto a Opti-Tof
384 well insert plate (Applied Biosystems, Carlsbad, CA,
USA). MALDI-TOF MS was performed using a 4800plus
MALDI-TOFTOF (Applied Biosystems, Carlsbad, CA,
USA) in the reflector mode with accelerating voltage of
20 kV, mass range of 800 to 4000 Da, 1000 shots/
spectrum and laser intensity of 2832. MSMS spectra
were performed automatically on twenty of most intense
precursors, with 1000 shots/spectrum and laser intensity
of 3700. Spectra were calibrated externally using a stand-
ard protein mixture (4700 Calmix, Applied Biosystems).
Alternatively, samples were dried and resuspended in
0.1% formic acid and analysed by LC-MSMS in a nano
Acquity (Waters, Milford, MA, USA) coupled to an
OrbitrapVelos (ThermoScientific, Waltham, MA, USA).
Sample was injected in a C18 phase reverse column
(75 μm i, 10 cm, nano Acquity, 1.7 μm BEH column,
Waters) in a gradient of 40-60% buffer B during 5 min-
utes at a flow rate of 250 nl/min (A: 0.1% formic acid; B:
ACN/0.1% acid formic). Eluted peptides were ionized by
ESI (PicoTipTM, New Objective 2000 V). Peptide mases
were analized in the Orbitrap in full scan (m/z 350–
1700) and the 5 most abundant peptides were selected
for collision-induced dissociation fragmentation using
helium as collision gas. Data were extracted with soft-
ware Thermo Xcalibur (v.2.1.0.1140).Protein identification
Proteins were identified using the search engine Mascot
and the Uniprot database. Search parameters used were:
human, missed cleavage 1, fixed modifications carbami-
domethyl (cysteines) and peptide tolerance 0.2 Da (MS)
0.3 Da (MSMS). Proteins with a score above 61 were
considered a positive hit.Human paraoxonase and complement C3 component
ELISA assays
Two commercial ELISA assays against paraoxonase
(Uscn Life Science Inc.) and complement C3 component
(AssayPro) were performed following manufacter’s
instructions. Assays were performed by duplicate in each
sample used in 2D-DIGE proteomic analysis. Results
were normalized by the total protein concentration. Data
are presented as μg (studied protein)/μg (total protein).Milliplex MAP assays
Two MILLIPLEXTM MAP assays (Millipore) were done.
Apolipoproteins apoAI, apoCIII, apoE and the acute-
phase protein serum amyloid A (SAA) were measured.
Analyses were performed as manufacturer suggested and
HDL dilutions were done in function of the sensibility of
the panel. Assays were performed by duplicate in each
sample used in 2D-DIGE proteomic analysis. Results
were normalized by the total protein concentration. Data
are presented as μg (studied protein)/μg (total protein).Statistical analysis
Continuous clinic and biochemical variables and protein
levels of ELISA and MILLIPLEX MAP assays were
expressed as median (interquartile range). Differences in
median values were assessed using Wilcoxon test. All
statistical analyses were performed with SPSS software
(version 15.0), with significance set at p < 0.05.Additional file
Additional file 1: Normalized volumes of differentially expressed
protein spot-features. The file is a table that shows the normalized
volumes of the spots that resulted statistically different in their
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